Re-biopsy

What it is

Re-biopsy is a second biopsy done after an earlier biopsy, often to get enough tissue or reassess disease after treatment, and one recent lung cancer study reported 113 CT-guided repeat needle biopsies. In plain language, it means taking another tissue sample from the same disease process when the first sample was inadequate, when the disease has changed, or when new treatment decisions depend on fresh pathology or molecular testing.

A biopsy removes cells or tissue so a laboratory can examine them under a microscope and, when needed, perform biomarker tests. Re-biopsy is not a single procedure. It can be done with a needle, through an endoscope, during bronchoscopy, or with a surgical approach, depending on where the abnormal tissue is and what information is needed.

In cancer care, re-biopsy is commonly considered in two situations:

1. The first biopsy did not answer the question. The sample may have been too small, crushed, necrotic, or non-representative.
2. The cancer has progressed or relapsed. A new sample may help confirm the diagnosis again, look for histologic change, or test for new biomarkers that can affect treatment choice.

This matters because imaging alone can show that a lesion is present or growing, but it usually cannot prove exactly what the tissue is. In India as elsewhere, re-biopsy is part of the care pathway in many oncology centres when treatment planning depends on updated tissue diagnosis or molecular profiling.

Common reason for re-biopsy	What clinicians are trying to learn
First biopsy inadequate	Whether enough tissue can be obtained for diagnosis
Cancer progression on treatment	Whether the tumour biology has changed
Need for biomarker testing	Whether targetable mutations or resistance markers are present
Suspicion of a different disease process	Whether infection, inflammation, scar tissue, or a second cancer is present

How it works

Re-biopsy works the same basic way as an initial biopsy: tissue is collected from a suspicious site and sent for pathology. The difference is the clinical purpose. Instead of making a first diagnosis only, the repeat sample may be used to answer a more specific question.

Depending on the case, the laboratory may do one or more of the following:

• routine histopathology to confirm cancer or another disease
• immunohistochemistry to classify the tumour more precisely
• molecular testing to look for mutations, fusions, or resistance changes
• microbiology studies if infection is a possibility

The site chosen for re-biopsy may be the original lesion or a new metastatic site. Doctors usually balance three issues before recommending it:

1. Expected benefit: Will a new sample likely change management?
2. Feasibility: Is there a lesion that can be reached safely?
3. Risk: Could the procedure cause bleeding, pneumothorax, infection, pain, or delay in treatment?

For example, a lung lesion may be sampled with CT-guided core needle biopsy, while a lymph node may be sampled with ultrasound guidance or endobronchial ultrasound. If tissue is hard to obtain safely, clinicians may also consider liquid biopsy in some cancers, but liquid biopsy does not fully replace tissue biopsy in every situation.

Evidence and uses

The strongest and most familiar use of re-biopsy in oncology is when the original sample is insufficient or when relapsed disease needs updated testing. A 2015 review on relapsed non-small cell lung cancer noted an important distinction: rebiopsy may refer to biopsy after cancer progression on initial therapy, while repeated biopsy may refer to a new biopsy because the first one was inadequate for diagnosis. In practice, patients and clinicians often use these terms interchangeably.

In non-small cell lung cancer, re-biopsy can help identify resistance mechanisms after targeted therapy or confirm whether the tumour has changed in type. This can directly affect treatment selection. A 2024 study comparing initial biopsy and repeat biopsy in patients with non-small cell lung cancer described 113 CT-guided repeat needle biopsies and defined success as obtaining sufficient malignant tissue. Such studies suggest that repeat biopsy is often feasible, but success depends on lesion size, location, operator technique, and the amount of viable tumour present.

Re-biopsy is not limited to cancer. In lupus nephritis, for example, repeat kidney biopsy may be considered during flare, persistent proteinuria, or even suspected remission because clinical findings do not always match what is happening in the kidney tissue. That broader medical use helps explain the term: re-biopsy is a care step used when fresh tissue information is clinically important.

Common settings where re-biopsy may be discussed include:

• lung cancer after progression on targeted therapy
• metastatic disease when a new lesion behaves differently
• lymphoma or other cancers when relapse needs confirmation
• a first biopsy that was nondiagnostic or insufficient for biomarkers
• non-cancer diseases where tissue changes over time affect treatment

When to see a clinician

Ask your treating clinician about re-biopsy if you have been told that your first biopsy was inconclusive, insufficient, or did not provide enough tissue for biomarker testing. You should also ask if scans show progression but the team is not certain whether this represents active cancer, treatment effect, infection, or another condition.

Questions worth asking include:

1. What exact question is the re-biopsy meant to answer?
2. Will the result change treatment options?
3. Which site will be biopsied and why?
4. What are the risks in my case?
5. Is liquid biopsy an option, and if so, what can it miss?

Seek urgent medical attention after any biopsy if you develop severe shortness of breath, chest pain, heavy bleeding, fever, worsening swelling, or fainting. These can signal complications that need prompt review.

Limitations and open questions

Re-biopsy can be very useful, but it has limits. A second sample may still be nondiagnostic if the lesion is small, hard to reach, mostly dead tissue, or biologically heterogeneous. One part of a tumour may not fully represent another part.

Evidence is strongest in some cancers, especially lung cancer, but less standardised in other settings. Studies often come from single centres, and results may not apply equally across hospitals, imaging methods, and operator experience. Even when re-biopsy is technically successful, it may not always produce enough high-quality material for all planned molecular tests.

Another open question is when tissue re-biopsy should be preferred over liquid biopsy. Blood-based testing is less invasive, but it may miss some alterations or fail when tumour DNA shedding is low. For that reason, clinicians often treat tissue and liquid biopsy as complementary rather than interchangeable.

The decision to do a re-biopsy is therefore individualised. It should consider the likely diagnostic yield, the chance that results will change management, the patient's overall condition, and the safety of the procedure.